Online Exclusives

Online Exclusives

Annual Cost to Treat CLL Projected to Increase Nearly 600 Percent Between 2011 and...

The annual cost to manage patients with chronic lymphocytic leukemia (CLL) will reach $5.13 billion by 2025, which is a 590 percent increase from...

UK’s NICE Recommends Bosutinib for Chronic Myeloid Leukemia

The U.K. National Institute for Health and Care Excellence (NICE) has recommended bosutinib for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia after working...

Investigational New Drug Application Opened for Tetulomab in Diffuse Large B-Cell Lymphoma

An Investigational New Drug Application for tetulomab injection has been opened with the U.S. Food and Drug Administration (FDA) for a second indication in...

New Compound Shows Potential to Block Cancer Growth for Multiple Hematologic Malignancies

The investigational compound S63845, a myeloid cell leukemia 1 (MCL1) inhibitor, was shown to potently kill MCL1-dependent cancer cells, including multiple myeloma, leukemia, and...

New CDC Report: Heart Disease and Cancer Responsible for Nearly Half of All U.S....

Cancer was the number two reported cause of death for Americans in 2014 – behind heart disease – resulting in 591,699 deaths, according to...

Study Finds Patients With Cancer May Have Unrealistic Expectations for Clinical Trials

A study published in Cancer found that many patients (>80%) who enroll in early-stage clinical trials (phase I) are motivated by the potential clinical...

Screening for Preleukemic Mutations Could Identify Patients Likely to Develop Therapy-Related Myeloid Neoplasms

Author’s Perspective Lead author Koichi Takahashi, MD: “Since many cancer patients are now living longer, t-MNs are an increasing concern for cancer survivors. Genetic mutations...

FDA Calls for Zika Virus Testing in All Donated Blood

The U.S. Food and Drug Administration (FDA) issued a revised guidance recommending universal testing of donated blood and blood components for Zika virus in...

National Health Spending Projected to Grow 17.8 Percent by 2025

Between 2015 and 2025, health spending growth in the United States is projected to average 5.8 percent, to total 20.1 percent of the total...

Comparing Bortezomib-Based Triplet Combinations for Newly Diagnosed Multiple Myeloma

The first head-to-head trial of bortezomib-based triplet combination therapies for patients with newly diagnosed multiple myeloma (MM) found that induction with a combination of...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.